31 of 31 requested axes resolved: no unsupported safe defaults, one hard concentration gate at 0.005%

Asked (summary)

Project ATLAS / ASTRA gap-only rotated authority review, 2026-09-14: resolve only the explicitly listed unresolved Safety & Usage axes — all 11 for Acetyl Hexapeptide-8, all 11 for Hydrogen Dimethicone, and 9 for isolated madecassoside (the locked teen and breastfeeding axes must not be repeated) — using exact identity and primary authorities, returning one disposition per axis under the ATLAS contract.

This review returns one disposition for each of the 31 requested axes across three cosmetic materials, and repeats 0 locked axes. It draws on 98 evidence rows gathered through 2026-09-14: 24 identity, authority and human-use rows for Acetyl Hexapeptide-8, 11 exact-CAS 68037-59-2 rows for Hydrogen Dimethicone, and 63 madecassoside tolerability and endpoint rows. No extract-to-isolate, copolymer-to-neat-polymer, or free-acid-to-amide transfer was used without a stated bridge.

Disposition matrix — 11 safety & usage axes by material

green — no concern after completed authority search (search closure, not clearance) teal — lower concern under tested conditions yellow — conditional restriction or explicit uncertainty orange — conflicting hazard evidence red — prohibited / avoid (none assigned) grey — locked axis, not re-reviewed

Hover or tap a cell for the disposition and its basis. The two grey madecassoside cells are the locked axes, shown only for completeness; they are not part of the 31 returned dispositions.

The CIR final report bridges INCI Acetyl Hexapeptide-8 to Acetyl Hexapeptide-8 Amide (CAS 616204-22-9, Ac-EEMQRR-NH2) and concludes it safe in cosmetics only at ≤0.005%; data above that are insufficient — cir-safety.org

PubChem also lists a distinct free-acid "Acetyl Hexapeptide-8 acid", so the CIR bridge applies only when the product specification confirms the C-terminal amide — pubchem.ncbi.nlm.nih.gov

For exact Hydrogen Dimethicone, ECHA C&L notifications conflict: 42.6% report no GHS classification while 33.2% report H315, 37.4% H319 and 24.2% H335 — conflicting evidence, not clearance — pubchem.ncbi.nlm.nih.gov

A 109-adult occlusive patch study of mascara with 0.5% madecassoside found mean irritation index 0.01 and no sensitization — support for formulation-limited lower concern only — cir-safety.org

Identity gates and exposure conditions

Acetyl Hexapeptide-8 — amide gate

The CIR conclusion attaches to the amidated peptide (CAS 616204-22-9, Ac-EEMQRR-NH2), which CIR states is synonymous with INCI Acetyl Hexapeptide-8 — cir-safety.org. Because a distinct free-acid record exists, every conditional cell requires the specification to confirm the amide and concentration ≤0.005%. Penetration data show ~0.01% of a 10% applied dose reaching the epidermis in vitro — pubmed.ncbi.nlm.nih.gov.

Hydrogen Dimethicone — exact CAS only

Only exact CAS 68037-59-2 evidence was used; no copolymer transfer. EU cosmetics law names it as a permitted coating material (Annex VI entry 27a), and FDA's 21 CFR 175 authorizations cover only a specified platinum-catalyzed food-contact reaction product — neither is a cosmetic safety clearance — accessdata.fda.gov. TSCA's ITC removed it from the priority testing list as a site-limited intermediate — 19january2021snapshot.epa.gov.

Madecassoside — tested-exposure gate

Support is exposure-limited: the 0.5% mascara HRIPT in 109 adults, a 20-woman six-month 0.1% topical study with no stated safety signal — pubmed.ncbi.nlm.nih.gov — and pure madecassoside tolerated at 5 mg/kg IV for 24 h in male rats — pubmed.ncbi.nlm.nih.gov. These support lower concern at or below 0.5% topical on intact skin, not unrestricted systemic or pregnancy safety.

The Hydrogen Dimethicone conflict, in numbers

Share of ECHA C&L notifications (289 reports) carrying each outcome for CAS 68037-59-2; a notification can carry several statements — pubchem.ncbi.nlm.nih.gov.

Evidence table

Material	Endpoint	Key result / conclusion	Exposure / population	Source

Gap-only rotated authority review under the ATLAS contract; searches through 2026-09-14. 98 evidence rows across four result sets (24 Acetyl Hexapeptide-8, 11 exact Hydrogen Dimethicone, 3 strongest plus 60 broader madecassoside rows); the table shows 30 decision-relevant rows and omits efficacy-only and duplicate records for space. Matrix cells state per-axis dispositions; percentages are shares of 289 ECHA C&L notifications. Regulatory search closure is distinct from safety clearance; every unresolved axis carries a specific endpoint, population, or data reason.

This report was generated automatically by Keenable SELECT at a user's request, from publicly available web sources linked herein. Keenable does not review, verify, or endorse its contents and makes no representation as to accuracy, completeness, or timeliness; AI-based extraction may contain errors. Nothing in this report is investment, legal, financial, or other professional advice. All trademarks and referenced content remain the property of their respective owners; no affiliation or endorsement is implied. To report an error, rights concern, or request removal: legal@keenable.ai.